The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients.
H. A. Henary
No relevant relationships to disclose
R. Kurzrock
No relevant relationships to disclose
G. S. Falchook
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. J. Wheler
No relevant relationships to disclose
A. M. Tsimberidou
No relevant relationships to disclose
J. Durand
No relevant relationships to disclose
P. Yang
Stock Ownership - Phoenix Biotechnology
Research Funding - Phoenix Biotechnology
M. J. Johansen
Consultant or Advisory Role - Scientific Advisory Board Member and Consultant
Stock Ownership - Phoenix Biotechnology
R. Newman
Consultant or Advisory Role - Phoenix Biotechnology
Stock Ownership - Phoenix Biotechnology
R. Khan
No relevant relationships to disclose
U. Patel
No relevant relationships to disclose
D. S. Hong
Research Funding - Eisai